Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION

https://doi.org/10.20996/1819-6446-2011-7-5-54-56

Full Text:

Abstract

Aim. To analyze the structure of expenses associated with warfarin dose adjustment and international normalized ratio (INR) control for patients with atrial fibrillation (AF) per 1 year of treatment. Material and methods. AF prevalence rate was calculated according to the large population studies data. The study was performed based on methodology for Cost of Illness evaluation. Expenses associated with INR monitoring within the obligatory medical insurance program were calculated based on the general tariff agreement for 2011 year for one of the territorial subject of Russia. Expenses associated with INR monitoring in outpatient departments of university clinics and commercial laboratories were calculated based on price list of respective institutes. Expenses associated with INR monitoring in case of self-monitoring were calculated based on expenses for portable coagulometer and test strips purchasing.  Results. Around 539 000 people in Russia are needed warfarin therapy and associated continuous INR monitoring. In the obligatory medical insurance program the cost of warfarin is less than 1% of total costs and the direct costs of treatment and control of nearly 4 058.12 RUR/person per year , in university clinics, respectively , 0.03%, and 13 019.05 RUR, in case of self-monitoring - 0.01-0.05% and from 40 405.00 (in the first year) to7 404.98 RUR (in the consequent years), respectively. Conclusion. The cost of warfarin, regardless of the INR monitoring approach is less than 1% of the total cost of the treatment with therapy efficacy and safety control.

About the Authors

Yu. B. Belousov
The Russian National Research Medical University named after N.I. Pirogov
Russian Federation


I. S. Yavelov
Research Institute of Physico-Chemical Medicine
Russian Federation


D. Yu. Belousov
Center of pharmacoeconomic studies
Russian Federation


E. V. Afanasieva
Center of pharmacoeconomic studies
Russian Federation


References

1. Skvortsova V.I., Stakhovskaya L.V., Ayriyan N.Yu. Epidemiology of stroke in the Russian Federation. Con-silium medicum 2003; 7(1): 10-12. Russian (Скворцова В.И., Стаховская Л.В., Айриян Н.Ю. Эпидемиология инсульта в Российской Федерации. Consilium medicum 2003; 7(1): 10-12).

2. Distribution of persons newly registered as disabled, for reasons of disability in the 2000 - 2010's. (Data Health Ministry of Russia, Rosstat calculations). Available on: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr4-2.xls. Date of access: 20.10.11. Russian (Распределение численности лиц, впервые признанных инвалидами, по причинам инвалидности в 2000 – 2010 гг. (Данные Минздравсоцразвития России, расчет Росстата). Доступно на: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr4-2.xls. Дата доступа: 20.10.11)

3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.

4. Kadykov A.S., Shakhparonova N.V. Vascular accident. Consilium medicum 2007; 5 (2): 74-77. Russian (Кадыков А.С., Шахпаронова Н.В. Сосудистая катастрофа. Consilium medicum 2007; 5 (2): 74-77).

5. Jones M., McEwan P., Morgan L-l.C., et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 2005;91:472–477.

6. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335(8): 540-6.

7. Björholt I, Andersson S, Nilsson G, Krakau I. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Family Practice 2007;8:6

8. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-2375.

9. General Agreement on Tariff St. Petersburg in 2011. Available on: http://www.spboms.ru/kiop/getdoc? doc_id=4778. Date of access: 20.10.11. Russian (Генеральное тарифное соглашение по г. Санкт-Пе-тербург на 2011 г. Доступно на http://www.spboms.ru/kiop/getdoc?doc_id=4778. Дата: 20.10.11).

10. Rowan B.S., Bailey D.N., Bublitz C.E., Anderson R.J. Trends in anticoagulation for atrial fibrillation in the U.S. An analysis of the National Ambulatory medical care survey database. J Am Coll Cardiol 2007;49:1561-5

11. Standard table equipment midwifery centers approved by the Ministry of Health 16.01.1991, the N 03-14/2-14. Available on: http://rudoctor.net/medicine2009/bz-dv/med-eqdyf.htm. Date of access: 20.10.11. Russian (Типовой табель оснащения фельдшерско-акушерских пунктов утверждён Министерством здравоохранения СССР 16.01.1991 г. N 03-14/2-14. Доступно на: http://rudoctor.net/medicine2009/bz-dv/med-eqdyf.htm. Дата доступа: 20.10.11).

12. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165(10): 1095-106.

13. Wittkowsky AK, Boccuzzi SJ, Wogen J, et al. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24(12): 1668-74.

14. Wittkowsky AK, Boccuzzi SJ, Wogen J, et al. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24(12): 1668-74.

15. Jones M., McEwan P., Morgan L-l.C. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 2005;91:472–477.

16. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 160S-198S.


For citation:


Belousov Y.B., Yavelov I.S., Belousov D.Y., Afanasieva E.V. ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2011;7(5):561-566. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-5-54-56

Views: 378


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)